Febuxostat is an orally administered, nonpurine-selective xanthine oxidase inhibitor approved by the Food and Drug Administration (FDA) in 2009 for the management of hyperuricemia in patients with gout (Hair et al., 2008; Kamel et al., 2017; Robinson and Dalbeth, 2018). The gene discussed is XDH; the disease is hyperuricemia.